Engineering antibodies with dual target capture
In the sphere of human antibody therapeutics, the DutaFab platform shows broadening potential. Pharmaceutical giant Roche has developed ‘dual targeting’ Fab molecules containing two spatially independent binding sites for targeting distinct antigens. Their recent study, published in Nature Communications, demonstrates the high efficacy of these bispecific monoclonal antibodies for VEGFA and PDGF-BB growth factors related